{"id":"NCT01614470","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation","officialTitle":"A Phase 3, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Crossover Study With an Open-Label Period to Evaluate the Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07","primaryCompletion":"2013-10","completion":"2013-10","firstPosted":"2012-06-08","resultsPosted":"2014-10-29","lastUpdate":"2014-10-29"},"enrollment":39,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"Ivacaftor","otherNames":["Kalydeco","VX-770"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Part 1: Ivacaftor First, Then Placebo","type":"EXPERIMENTAL"},{"label":"Part 1: Placebo First, Then Ivacaftor","type":"EXPERIMENTAL"},{"label":"Part 2: Ivacaftor","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have a non-G551D cystic fibrosis transmembrane regulator (CFTR) gating mutation (any one of the following CFTR mutations: G178R, G551S, S549N, S549R, G970R, G1244E, S1251N, S1255P, or G1349D).","primaryOutcome":{"measure":"Part 1: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8","timeFrame":"Part 1: Baseline (pre-dose Day 1), Week 8","effectByArm":[{"arm":"Part 1: Ivacaftor","deltaMin":76.3659,"sd":20.3345},{"arm":"Part 1: Placebo","deltaMin":79.3361,"sd":20.83991}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":9},"locations":{"siteCount":12,"countries":["United States","Belgium","France"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":38},"commonTop":["Cough","Infective pulmonary exacerbation of cystic fibrosis","Headache","Sputum increased","Abdominal pain"]}}